LOTO BIOTECH PLATFORM

The company is an innovative startup specializing in the digitalization of the development process for siRNA therapies targeting rare and genetic diseases, with the goal of addressing approximately 7,000 rare genetic diseases that currently lack treatment. Through a proprietary platform supported by Machine Learning, the startup accelerates and enhances the efficiency of pro-drug research, reducing both development time and costs. In the short term, the company aims to provide valid candidates to pharmaceutical companies for testing phases; in the long term, it plans to manage the entire production process and clinical trials in-house. The success of this venture will depend on the continuous technological advancement of the platform, the ability to navigate complex regulatory processes, and an effective marketing strategy to educate the market on the innovative solutions offered. LOTO Biotech aims to address the need for effective treatments for rare diseases, where therapeutic options are often limited or nonexistent. Thanks to its advanced platform based on proprietary algorithms protected by trade secrets, the company can develop innovative pro-drugs, offering a significant competitive advantage in terms of development time and cost. The platform has already demonstrated initial success in developing molecules for the treatment of specific diseases, supported by positive pre-clinical tests. Currently, LOTO is working on filing its first patents for diseases of particular interest, such as MMIHS, Osteogenesis Imperfecta, and Marfan Syndrome. The market for rare disease drugs is rapidly expanding, with an expected annual growth rate of 10-15%. Innovative RNA-based treatments are gaining significant interest due to their ability to target specific genetic mutations. The overall market value for rare disease drugs is projected to exceed €300 billion by 2030, presenting significant opportunities for LOTO Biotech to leverage its cutting-edge technology. While there are competitors in the biotechnology sector and RNA therapy development, LOTO Biotech stands out due to its platform based on unique algorithms and a trade secret approach that ensures the protection of its technological know-how. Additionally, the focus on specific rare diseases and partnerships with advanced research institutions provide a strong competitive advantage. The LOTO Biotech team comprises experts in biotechnology and genetic engineering with extensive experience in both academic and applied research. The founders include researchers who have contributed to numerous patents and significant scientific publications, solidifying a network of collaborations with international centers of excellence. The operational plan outlines a lean and agile organizational structure focused on research and development (R&D), supported by strategic partnerships for access to technical and production resources. The production model will initially rely on outsourcing to minimize fixed costs and facilitate rapid scalability. The financial plan for the first four years demonstrates sustained revenue growth and profitability starting from the third year. The plan shows a gradual reduction in operational costs relative to revenue, with a steady increase in the gross margin from 93.55% in the second year to 97.59% in the fourth year. LOTO Biotech plans to develop seven patents within the first two years, requiring an investment of €1,500,000 to support R&D activities, patent filings, and initial marketing and commercialization operations. The main risks include regulatory barriers and competition from other advanced biotechnologies. However, the protection offered by trade secrets and the adoption of a patent licensing strategy mitigate exposure to competitive and financial risks. LOTO Biotech represents a unique opportunity to invest in an innovative and scalable project aimed at revolutionizing the treatment of rare diseases, creating value for both investors and patients worldwide.